Bio Medica Laboratories Limited is engaged in the manufacturing of pharmaceutical parenteral formulations. The company manufactures injectable formulations in two main categories — liquid injectables and dry powder injectables. These products are available in both single-dose and multi-dose formats and cater to human and veterinary healthcare needs.
The company has a diversified product portfolio, comprising 58 products in the liquid injectables category and 15 in the dry powder injectables category. Its offerings include generic drugs, branded pharmaceuticals, over-the-counter products, and other medications. The injectables are mainly packed in ampoules and vials, depending on the product type and dosage requirement.
Bio Medica Laboratories operates on a B2B contract manufacturing model. The company does not sell directly to end users; instead, it manufactures formulations for other pharmaceutical companies as per their specific requirements and product specifications. These customers market the products under their own names, while Bio Medica Laboratories acts as the manufacturer.
The company holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificates issued by the Food & Drugs Administration, Madhya Pradesh. It also has an in-house quality control setup to test raw materials and finished goods, helping the company maintain quality standards throughout the manufacturing process.
Bio Medica Laboratories has two manufacturing facilities, both located in Indore, Madhya Pradesh.
Bio Medica Laboratories IPO – Details
| IPO Opening Date | 21 May 2026 |
| IPO Closing Date | 25 May 2026 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue: 37,72,000 Shares Worth ₹52.43 Crore Fresh Issue: 33,95,000 Shares Worth ₹47.19 Crore Offer For Sale: 3,77,000 Shares Worth ₹5.24 Crore |
| Face Value | ₹10 per equity share |
| IPO Price | ₹132 – ₹139 per share |
| Market Lot | 1000 Shares |
| Min Order | 1000 Shares [ 1 Lot ] |
| Listing At | NSE SME |
| Registrar | Skyline Financial Services Pvt. Ltd. |
| QIB Shares Offered | 1.00% |
| NII Shares Offered | 48.98% |
| Retail Shares Offered | 50.01% |
Bio Medica Laboratories IPO – Date Schedule
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Initiation of Refund | 27 May 2026 |
| Credit of Shares to Demat | 27 May 2026 |
| IPO Listing Date | 29 May 2026 |
| Cut-off time for UPI mandate confirmation | 5 PM on May 25, 2026 |
Bio Medica Laboratories IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2000 | ₹2,78,000 |
| Retail (Max) | 2 | 2000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8000 | ₹11,12,000 |
Competitive Strength
- Multi-product capability and diversified product portfolio.
- Experienced promoters, management and employees.
- Quality assurance.
- Established client relationship.
Company Promoters
- Mr. Mukesh Mehta
- Mr. Pradeep Mehta
Company Financials
| Period | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2023 | ₹16.25 Cr | ₹15.80 Cr | ₹0.33 Cr | ₹9.61 Cr |
| 31 March 2024 | ₹15.34 Cr | ₹11.69 Cr | ₹2.50 Cr | ₹10.49 Cr |
| 31 March 2025 | ₹38.33 Cr | ₹25.18 Cr | ₹9.79 Cr | ₹15.01 Cr |
| 30 November 2025 | ₹28.63 Cr | ₹16.95 Cr | ₹8.66 Cr | ₹38.17 Cr |
Key Performance Indicator
| KPI | Values (Nov 30, 2025) |
|---|---|
| ROE | 54.41% |
| ROCE | 23.22% |
| Debt/Equity | 2.23 |
| RoNW | 54.41% |
| PAT Margin | 30.35% |
| EBITDA Margin | 47.11% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 10.67 | 10.33 |
| P/E (x) | 13.03 | 13.45 |
Object Of The Issue
| Objects of the Issue | Expected Amount (in Crore) |
|---|---|
| Repayment of loan. | ₹6.50 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises. | ₹28.50 |
| General corporate purposes. | – |
✅Strengths
- Experienced promoters with over 37 years of experience in the pharmaceutical industry.
- GMP and GLP certified manufacturing setup.
- In-house quality control team for raw material and finished product testing.
- Diversified product portfolio with 71 formulations/products.
- Ability to manufacture both liquid and dry powder injectables.
- Established client relationships with repeat orders.
- Low employee attrition supports workforce stability.
⚠️Risks
- Production at Manufacturing Unit-I is suspended due to regulatory non-compliances.
- Heavy dependence on Manufacturing Unit-II may create operational pressure.
- High customer concentration; top 10 customers contributed 76.45% of revenue up to November 30, 2025.
- Any manufacturing or quality control issue can damage reputation and lead to liabilities.
- Company does not carry product liability insurance.
- Future regulatory inspections may result in adverse findings or actions.
- Dependence on third-party transport providers may affect raw material supply and product delivery.
- Delay in adopting new technology may impact competitiveness.
Bio Medica Laboratories IPO Promoter Holding
| Pre-Issue Share Holding | 99.99% |
| Post Issue Share Holding | – |
Bio Medica Laboratories IPO Prospectus
- Bio Medica Laboratories IPO DRHP
- Bio Medica Laboratories IPO RHP
Company Contact Information
| Bio Medica Laboratories Limited Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015 Phone: +91 7314102751 Email: companysecretary@biomedica.co.in Website: https://biomedica.co.in/ |
Bio Medica Laboratories IPO Registrar
| Skyline Financial Services Pvt. Ltd. Phone: 02228511022 Email: ipo@skylinerta.com Website: https://www.skylinerta.com/ipo.php |
Bio Medica Laboratories IPO Lead Manager(s)
| 1. Narnolia Financial Services Ltd. |
Bio Medica Laboratories IPO FAQ
| What is the Bio Medica Laboratories IPO? Bio Medica Laboratories IPO is an SME IPO. The issue is priced at ₹132 – ₹139 per equity share. The IPO is to be listed on NSE SME. |
| When will Bio Medica Laboratories IPO open? The IPO is to open on 21 May 2026 for QIB, NII, and Retail Investors. |
| What is Bio Medica Laboratories IPO Investors’ Portion? The investors’ portion for QIB – 1.00%, NII – 48.98%, and Retail – 50.01%. |
| What is the Bio Medica Laboratories IPO Size? Bio Medica Laboratories IPO size is ₹52.43 Crore. |
| What are the Bio Medica Laboratories IPO Minimum and Maximum Lot Sizes for Retail Investors? The minimum bid is 2000 Shares for ₹2,78,000, while the maximum bid is 2000 Shares for ₹2,78,000. |
| What is the Bio Medica Laboratories IPO Allotment Date? Bio Medica Laboratories IPO allotment date is 26 May 2026. |
| What is the Bio Medica Laboratories IPO Listing Date? Bio Medica Laboratories IPO listing date is 29 May 2026. The IPO is to be listed on the NSE SME. |
